Trial Profile

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rapamycin resistant T-cell therapy (Primary) ; Cyclophosphamide; Pentostatin
Indications Multiple myeloma
Focus Therapeutic Use
Sponsors Rapa Therapeutics

Most Recent Events

15 May 2025 Status changed from recruiting to completed.
14 Dec 2021 Interim results (n=6; data cut off date- 1 Aug 2021) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
19 Oct 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com